硝酸纤维素 | 136468-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 硝酸纤维素
• 英文名称: 5-methoxy-6-methyl-2-aminoindan
• 英文别名: 5-methoxy-6-methyl-2-aminoindane；5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine
• CAS: 136468-19-4
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: JLESVLCTIOAHPT-UHFFFAOYSA-N

物化性质

• 沸点：
  286.8±40.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硝酸纤维素 在 盐酸 作用下， 以 水 、 乙酸乙酯 为溶剂， 以91.89g的产率得到MMAI(盐酸盐)
  参考文献：
  名称：

  一种2-氨基茚满衍生物的合成方法及其产品

  摘要：

  本发明提供了一种2‑氨基茚满衍生物的合成方法，即以5,6二取代1‑茚酮为起始原料，先进行溴化反应，再进行盖布瑞尔反应，接着加入水合肼，进行水解反应同时生成腙，最后在高沸点溶剂中加入强碱进行加热水解，制得目标产物2‑氨基茚满衍生物。本发明还提供了由上述合成方法制得的2‑氨基茚满衍生物。与现有技术中的2‑氨基茚满衍生物合成方法相比，本发明所提供的合成方法反应原料廉价，反应条件温和，反应步骤简单，易于操作，并且所得产品的收率较高，适于工业化生产，因此，具有很好的应用前景与市场潜力。

  公开号：

  CN105884626B
• 作为产物：
  描述：

  3-甲氧基-4-甲基苯甲醛 在 palladium on activated charcoal 哌啶 、 吡啶 、 盐酸 、 草酰氯 、 硫酸 、 氢气 、 四氯化锡 、 N,N-二甲基甲酰胺 、 亚硝酸异戊酯 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 溶剂黄146 、 苯 为溶剂， 25.0~45.0 ℃ 、413.69 kPa 条件下， 反应 34.75h， 生成 硝酸纤维素
  参考文献：
  名称：

  Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)

  摘要：

  The racemate and the enantiomers of 1-(3-methoxy-4-methylphenyl)-2-aminopropane (6) and racemic 5-methoxy-6-methyl-2-aminoindan (11) were tested for stimulus generalization in the two-lever drug-discrimination paradigm. Both 6 and 11 were found to substitute with high potency in 3,4-(methylenedioxy)methamphetamine (1) and (S)-1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (2) trained rats. In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel. Racemic 6, but not 11, partially substituted for LSD. Racemic 6 and 11 did not substitute in (S)-amphetamine-trained rats. All of the test compounds were potent inhibitors of [H-3]-5-HT uptake into synaptosomes in vitro, with the S enantiomer of 6 being most active. Rat brain monoamine levels were unaltered 1 week following a single high dose (10 or 20 mg/kg, sc) of 6 or 11, or two weeks following a subacute dosing regimen (20 mg/kg, sc, twice a day for 4 days). In addition, radioligand-binding parameters in rat brain homogenate with the 5-HT uptake inhibitor [H-3]proxetine were unchanged after subacute dosing with either racemic 6 or 11. The results indicate that compounds 6 and 11 have animal behavioral pharmacology similar to the methylenedioxy compounds 1 and 2, but that they do not induce the serotonin neurotoxicity that has been observed for the latter two drugs.

  DOI：

  10.1021/jm00109a020

文献信息

• [EN] CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZÈNESULFONAMIDES CYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009080223A1

  公开（公告）日：2009-07-02

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the Formula (I), in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  该发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，显示出PPARδ或PPARδ和PPARγ激动剂活性。所描述的是Formula (I)的化合物，其中基团如所定义，并且它们的生理上可接受的盐及其制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗相关的疾病，以及中枢和外周神经系统的脱髓鞘化和其他神经退行性疾病。
• Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
  申请人：SCHOENAFINGER Karl

  公开号：US20110224263A1

  公开（公告）日：2011-09-15

  The invention relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及环状N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理功能衍生物，表现出PPARdelta或PPARdelta和PPARgamma激动剂活性。所描述的是式I的化合物，其中基团的定义如上所述，以及它们的生理上可接受的盐和制备过程。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用紊乱以及胰岛素抵抗涉及的疾病，以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• Composition comprising cocoa
  申请人：——

  公开号：US20020172732A1

  公开（公告）日：2002-11-21

  The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviating depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and/or reduced libido, The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

  本发明涉及一种用于治疗情绪障碍，尤其是治疗、预防或缓解抑郁、情绪障碍或情绪不足、肥胖、超重、经前综合征、渴望、渴望碳水化合物、渴望巧克力、更年期不适、勃起功能障碍和/或性欲减退的组合物和方法。
• COMPOSITION COMPRISING COCOA AND A DOPAMINE D2 RECEPTOR AGONIST
  申请人：N.V. Nutricia

  公开号：EP1370273A1

  公开（公告）日：2003-12-17
• US8344004B2
  申请人：——

  公开号：US8344004B2

  公开（公告）日：2013-01-01